Rankings
▼
Calendar
IMNM FY 2021 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena
IMNM
Immunome, Inc.
$2B
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$25M
Net Income
-$25M
EPS (Diluted)
$-2.14
Cash Flow
Operating Cash Flow
-$18M
Free Cash Flow
-$18M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$58M
Total Liabilities
$10M
Stockholders' Equity
$48M
Cash & Equivalents
$49M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
-$755,000
+100.0%
Operating Income
-$25M
-$12M
-105.6%
Net Income
-$25M
-$18M
-38.5%
← Q4 2020
All Quarters
Q1 2021 →